James Batey, MD
Family Medicine · Union City, TNNPI 1235119033
Payments from drug & device makers
Across 503 payments — averaging $130.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$58K
- Novo Nordisk$2K
- AbbVie$1K
- Lilly USA, LLC$1K
- Boehringer Ingelheim$835
- AstraZeneca$578
- plus $2K from 29 others
What the payments were for
- Food & beverage$7,92499%
- Education$531%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 28 | $58,026 |
| Novo Nordisk | 107 | $1,904 |
| AbbVie(2 entities) | 74 | $1,090 |
| Lilly USA, LLC | 88 | $1,027 |
| Boehringer Ingelheim | 56 | $835 |
| AstraZeneca | 19 | $578 |
| Johnson & Johnson | 19 | $353 |
| Bayer | 17 | $312 |
| GSK | 16 | $259 |
| Phathom Pharmaceuticals, Inc. | 15 | $238 |
| Astellas Pharma US Inc | 8 | $145 |
| Dexcom, Inc. | 5 | $109 |
| Novartis | 6 | $98 |
| Exact Sciences | 4 | $97 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $76 |
| Amgen(2 entities) | 5 | $69 |
| Sumitomo Pharma America, Inc. | 3 | $67 |
| Otsuka America Pharmaceutical, Inc. | 4 | $66 |
| Merck | 4 | $53 |
| Gilead | 3 | $44 |
| Sanofi Pasteur Inc. | 3 | $42 |
| Idorsia Pharmaceuticals US Inc | 2 | $31 |
| Paratek Pharmaceuticals, Inc. | 1 | $25 |
| Abbott | 1 | $23 |
| Genentech USA, Inc. | 1 | $23 |
| Teva Pharmaceuticals USA, Inc. | 1 | $21 |
| Bristol Myers Squibb | 1 | $19 |
| Shire North American Group Inc | 1 | $18 |
| Ironwood Pharmaceuticals, Inc | 1 | $17 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $17 |
| Eisai Inc. | 1 | $15 |
| Esperion Therapeutics, Inc. | 1 | $15 |
| Medtronic | 1 | $14 |
| Mylan Specialty L.p. | 1 | $11 |
| Ultragenyx Pharmaceutical Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$65,748 in reported general payments places this provider in the 95th percentile of 2,087 family medicine providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 179 | $198,515 |
| FarxigaDapagliflozin Propanediol | 121 | $124,058 |
| OzempicSemaglutide | 111 | $116,106 |
| Sandostatin Lar DepotOctreotide Acetate,mi-Spheres | 12 | $81,180 |
| EliquisApixaban | 79 | $76,349 |
| MounjaroTirzepatide | 64 | $69,912 |
| JanuviaSitagliptin Phosphate | 50 | $59,468 |
| XareltoRivaroxaban | 45 | $54,988 |
| TrulicityDulaglutide | 38 | $53,810 |
| Tresiba Flextouch U-200Insulin Degludec | 42 | $29,501 |
| VraylarCariprazine Hcl | 21 | $28,704 |
| RybelsusSemaglutide | 23 | $28,590 |
| JanumetSitagliptin Phos/Metformin Hcl | 32 | $26,933 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 21 | $22,597 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 30 | $20,969 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $835 | $198,515179 claims |
| Novo NordiskOzempic, Rybelsus | $1,904 | $144,696134 claims |
| AstraZenecaFarxiga | $578 | $124,058121 claims |
| Lilly USA, LLCMounjaro, Trulicity | $1,027 | $123,721102 claims |
| MerckJanuvia, Janumet, Janumet Xr | $53 | $107,370112 claims |
| NovartisSandostatin Lar Depot | $98 | $81,18012 claims |
| PfizerEliquis | $58,026 | $76,34979 claims |
| Johnson & JohnsonXarelto | $353 | $54,98845 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $259 | $39,63742 claims |
| AbbVieVraylar, Synthroid | $1,090 | $31,06660 claims |
| Astellas Pharma US IncMyrbetriq | $145 | $15,58020 claims |
| BayerKerendia | $312 | $12,97215 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,087 family medicine providers in Tennessee.
Other family medicine in Union City
- Rickey ManningKnoxville$8.1M
- Kymberly MoyerGallatin$5.9M
- Natasha BallardChattanooga$5.7M
- Hina BudhwaniNashville$4.7M
- Paul WakefieldKnoxville$4.3M
- Emily HubbsKingsport$2.8M
- Jerry PunchKnoxville$2.1M
- Bridgette FraneyNashville$2M
- Andrew BrockmyreBristol$1.8M
- Marcus LeeTullahoma$1.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.